EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial

Caroline Moreau, Pascal Odou, Julien Labreuche, Alexandre Demailly, Gustavo Touzet, Nicolas Reyns, Bastien Gouges, Alain Duhamel, Christine Barthelemy, Damien Lannoy, Natacha Carta, Benjamin Palas und 15 weitere

Nature Medicine · 2025

DOI: 10.1038/s41591-024-03428-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nature Medicine, 2025. Verfasst von Caroline Moreau und 26 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Disease Centre of Excellence, Department of Neurology, Univeristy of Lille, CHU Lille, INSERM U1172-Degenerative & Vascular Cognitive Dis…. Hauptthemen laut MEDLINE: Antiparkinson Agents, Dopamine, Levodopa, Parkinson Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: InBrain Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Continuous compensation for cerebral dopamine deficiency represents an ideal treatment for Parkinson's disease. Dopamine does not cross the digestive and blood-brain barriers and is rapidly oxidized. The new concept is the intracerebroventricular administration of anaerobic dopamine (A-dopamine) using an abdominal pump connected to a subcutaneous catheter implanted in the third ventricle, near the striatum. An open-label phase 1 study showed no serious adverse reactions induced by A-dopamine in 12 patients. A randomized, controlled, open-label, crossover phase 2 study of 1 month of A-dopamine versus 1 month of optimized oral antiparkinsonian therapy was conducted in 9 patients. The primary endpoint, a blinded assessment of the percentage over target (that is, time with dyskinesia or bradykinesia), recorded by home actimetry using a wristwatch, was significantly reduced on A-dopamine compared with that on oral treatment alone (P = 0.027), with a median within-patient difference of -10.4 (Hedge g = -0.62 (95% confidence interval: -1.43, -0.08)). Home diaries were also significantly improved. These initial data on the feasibility, safety and effects of this new device-assisted therapy suggest validation by a large randomized double-blind trial. ClinicalTrials.gov registration: NCT04332276 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiparkinson AgentsDopamineLevodopaParkinson DiseaseAgedFemaleHumansMaleMiddle AgedAnaerobiosisCross-Over Studies

Substanzen

Antiparkinson AgentsDopamineLevodopa

Autor:innen und Institutionen

  • Parkinson's Disease Centre of Excellence, Department of Neurology, Univeristy of Lille, CHU Lille, INSERM U1172-Degenerative & Vascular Cognitive Disorders, Lille, France.
  • GRITA ULR 7365, University of Lille, Lille, France.
  • Pharmacy CHU Lille, Lille, France.
  • Department of Biostatistics, University of Lille, CHU de Lille, Lille, France.
  • InBrain Pharma, Lille, France.
  • Neurosurgery Department, University of Lille, CHU Lille, Lille, France.

Förderung

  • InBrain Pharma

Zitieren

APA

Moreau, C., Odou, P., Labreuche, J., Demailly, A., Touzet, G., Reyns, N., Gouges, B., Duhamel, A., Barthelemy, C., Lannoy, D., Carta, N., Palas, B., Vasseur, M., Marchand, F., Ollivier, T., Leclercq, C., Potey, C., Ouk, T., Baigne, S., …, & Devos, D. (2025). Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03428-2

Vancouver

Moreau C, Odou P, Labreuche J, Demailly A, Touzet G, Reyns N, et al. Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial. Nature Medicine. 2025. doi:10.1038/s41591-024-03428-2

BibTeX
@article{Moreau2025,
  author = {Moreau, Caroline and Odou, Pascal and Labreuche, Julien and Demailly, Alexandre and Touzet, Gustavo and Reyns, Nicolas and Gouges, Bastien and Duhamel, Alain and Barthelemy, Christine and Lannoy, Damien and Carta, Natacha and Palas, Benjamin and Vasseur, Michèle and Marchand, Felix and Ollivier, Thomas and Leclercq, Céline and Potey, Camille and Ouk, Thavarak and Baigne, Simon and Dujardin, Kathy and Carton, Louise and Rolland, Anne Sophie and Devedjian, Jean Christophe and Foutel, Véronique and Deplanque, Dominique and Fisichella, Matthieu and Devos, David},
  title = {Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial},
  journal = {Nature Medicine},
  year = {2025},
  doi = {10.1038/s41591-024-03428-2}
}
Kostenlos starten →